STOCK TITAN

Ultragenyx to Present at Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Jefferies Global Healthcare Conference on June 8, 2022, at 2:30 PM ET, in New York. The presentation will focus on the company's commitment to developing therapies for serious rare genetic diseases. A live and archived webcast will be available on their website for 90 days post-event. Ultragenyx aims to deliver effective treatments efficiently, addressing high unmet medical needs in rare diseases.

Positive
  • None.
Negative
  • None.

NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 2:30 PM ET in New York.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors  
Joshua Higa 
ir@ultragenyx.com  

Media  
Jeff Blake 
415-612-7784 
media@ultragenyx.com


FAQ

When will Ultragenyx present at the Jefferies Global Healthcare Conference?

Ultragenyx will present on June 8, 2022, at 2:30 PM ET.

Where can I watch the Ultragenyx presentation?

The presentation can be viewed live and archived on Ultragenyx's website.

What is Ultragenyx Pharmaceutical focused on?

Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.

What is the stock symbol for Ultragenyx Pharmaceutical?

The stock symbol for Ultragenyx Pharmaceutical is RARE.

How long will the Ultragenyx webcast be available?

The webcast of the presentation will be available for 90 days.

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

RARE Rankings

RARE Latest News

RARE Stock Data

4.01B
88.07M
3.62%
97.49%
3.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NOVATO